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15-Hydroxyprostaglandin dehydrogenase (15-PGDH) catalyzes the conversion of oncogenic prostaglandin E2 to non-tumerigenic 15-keto prostaglandin E2. In the
present study, we found that curcumin, a yellow coloring agent present in the rhizome of Curcuma longa Linn (Zingiberaceae), induced expression of 15-PGDH at the both
transcriptional and translational levels in normal rat gastric mucosal cells. By using deletion constructs of 15-PGDH promoter, we were able to demonstrate that activator
protein-1 (AP-1) is the principal transcription factor responsible for regulating curcumin-induced 15-PGDH expression. Curcumin enhanced the expression of c-Jun and c-
Fos that are functional subunits of AP-1, in the nuclear fraction of cells. Silencing of c-Jun suppressed curcumin-induced expression of 15-PGDH. Moreover, the chromatin
immunoprecipitation assay revealed curcumin-induced binding of c-Jun to the AP-1 consensus sequence present in the 15-PGDH promoter. Curcumin increased
phosphorylation of ERK1/2 and JNK, and pharmacologic inhibition of these kinases abrogated the curcumin-induced phosphorylation of c-Jun and 15-PGDH expression. In
contrast, tetrahydrocurcumin which lacks the α,β-unsaturated carbonyl group failed to induce 15-PGDH expression, suggesting that the electrophilic carbonyl group of
curcumin is essential for its induction of 15-PGDH expression. Curcumin restored the expression of 15-PGDH which is down-regulated by Helicobacter pylori through
suppressionofDNAmethyltransferase1. In addition, oral administrationof curcumin increased the expressionof 15-PGDHand its regulators suchas p-ERK1/2, p-JNK, and c-
Jun in the mouse stomach. Taken together, these findings suggest that curcumin-induced upregulation of 15-PGDH may contribute to chemopreventive effects of this
phytochemical on inflammation-associated gastric carcinogenesis.
© 2020 Elsevier Inc. All rights reserved.Keywords: Curcumin; 15-Hydroxyprostagladin dehydrogenase; AP-1; Anti-inflammation; Stomach1. Introduction
Cyclooxygenase-2 (COX-2), a rate-limiting enzyme in the arachi-
donic acid cascade, catalyzes the biosynthesis of prostaglandin E2
(PGE2) upon inflammatory insults [1,2]. Overproduction of PGE2
stimulates proliferation of various cancer cells, confers resistance to
apoptosis of cancerous cells, and accelerates metastasis and angio-Abbreviations: AP-1, Activator protein-1; COX-2, Cyclooxygenase-2; CDDO
Dichlorofluorescein diacetate; DNMT1, DNA methyltransferase 1; 15d-PGJ2, 15-
HDAC, Histone deacetylase; Helicobacter pylori, H. pylori; JNK, c-Jun N-terminal kina
protein kinases; NAC,N-Acetyl-L-cysteine; NF-κB, Nuclear factor-κB; 15-PGDH, 15-H
mucosal; ROS, Reactive oxygen species
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0955-2863/© 2020 Elsevier Inc. All rights reserved.genesis [3]. An intracellular level of PGE2 is regulated not only by COX-
2 but also by 15-hydroxyprostaglandin dehydrogenase (15-PGDH).
15-PGDH oxidizes the 15-hydroxyl group of PGE2 to generate 15-keto
prostaglandin E2 (15-keto PGE2) [4].
A low level of 15-PGDH has been observed in various tumors,
including those of colon, gastric, lung, bladder and breast [5–9]. One of
the molecular mechanisms underlying down-regulation of 15-PGDH-Me, 2-cyano-3,12-dioxooleana-1,9(11)-dien-C28-Methyl ester; DCF-DA,
deoxy Δ12,14-prostaglandin J2; ERK, Extracellular signal-regulated kinases;
se; 15-keto PGE2, 15-keto prostaglandin E2; MAP kinases, Mitogen-activated
ydroxyprostaglandin dehydrogenase; PGE2, Prostaglandin E2; RGM, Rat gastric
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15-PGDH provoked increased susceptibility to tumor induction
through aberrant accumulation of PGE2 [8,10]. In contrast, overex-
pression of 15-PGDH in various cancer cells suppressed proliferation,
invasion, metastasis, angiogenesis, and tumor-induced immune
suppression while promoting apoptosis [11–14]. Furthermore, 15-
PGDH also sensitizes the cancer cells to chemotherapeutic agents [15].
Some peroxisome proliferator-activated receptor γ (PPARγ)
ligands, histone deacetylase (HDAC) inhibitors, and non-steroidal
anti-inflammatory drugs have been reported to increase 15-PGDH
expression/activity [16–18]. Therefore, 15-PGDH has been considered
as a molecular target for cancer chemoprevention and therapy [19]. In
our previous study, an endogenous PPARγ ligand, 15-deoxy Δ12,14-
prostaglandin J2 (15d-PGJ2) induced the expression of 15-PGDH in
breast [16] and colon [20] cancer cells. Treatment of MDA-MB-231
cells with 15d-PGJ2 induced demethylation of CpG island of 15-PGDH
promoter through suppression of DNA methyltransferase (DNMT),
leading to reduced migration of these cells [16,21].
The synthetic chemopreventive triterpenoid 2-cyano-3,12-
dioxooleana-1,9(11)-dien-C28-methyl ester (CDDO-Me) upregulated
the expression of 15-PGDH, whichwas associatedwith suppression of
proinflammatory cytokine production and proliferation of colon
epithelial cells [22]. Expression of 15-PGDH is also regulated by
transforming growth factor-β [23]. Knockout of Smad3, a downstream
target of transforming growth factor-β signaling, abolished the CDDO-
Me-induced 15-PGDH expression [22]. In addition, elevated expres-
sion ofHDACcorrelatedwithdown-regulation of 15-PGDH,whichwas
attributable to interaction of Snail with the promoter of 15-PGDH [17].
In contrast, HDAC inhibitors such as scriptaid, apicidin, sodium
butyrate and oxamflatin induced the expression of 15-PGDH in lung
adenocarcinoma by augmenting acetylation of histones H3 and H4 in
the 15-PGDH promoter [23]. In addition, 15-PGDH is speculated to
function as an antagonist of COX-2, and there is a reciprocal
relationship between COX-2 and 15-PGDH [13]. Some natural
compounds exert their chemopreventive effects through up-
regulation of 15-PGDH,while down-regulating COX-2 expression [24].
Curcumin, a yellow coloring ingredient of turmeric (Curcuma
longa L., Zingiberaceae), has anti-oxidative and anti-inflammatory
properties, which contribute to majority of its health beneficial
effects [25,26]. One of the well-defined molecular mechanisms by
which curcumin exerts anti-inflammatory and anti-carcinogenic
effects is suppression of intracellular signaling responsible for
COX-2 expression [27]. Curcumin has been shown to inhibit the
expression of COX-2 in various preclinical studies by blocking the
activation of the transcription factor NF-κB [28–30]. By down-
regulating COX-2 expression, curcumin also inhibited production
of PGE2 induced by lipopolysaccharide in Raw264.7 murine
macrophages [31].
If curcumin exerts its anti-inflammatory effect by reducing the
tissue or circulating level of PEG2, thismay bemediated by stimulating
the catabolism of PGE2 as well as reducing its biosynthesis. In this
study, we investigated the effects of curcumin on 15-PGDH expression
and underlying molecular mechanisms in cultured rat gastric mucosa
(RGM)-1 cells and mouse stomach in vivo.
2. Materials and methods
2.1. Materials
Curcumin was purchased from the Sigma-Aldrich (St. Louis, MO,
USA). Tetrahydrocurcumin prepared by the catalytic hydrogenation of
curcumin was generously supplied by Prof. Jeewoo Lee, College of
Pharmacy, Seoul National University. Dulbecco's modified Eagle's
medium (DMEM), fetal bovine serum, penicillin and Trizol® reagent
were products of GIBCO BRL (Grand Island, NY, USA). U0126 andSP600125 were purchased from TOCRIS (Ellisville, MO, USA). Protease
inhibitor cocktail was provided from Boehringer Mannheim (Mann-
heim,Germany). Bicinchoninic acid protein assay reagentwas aproduct
of Pierce Biotechnology (Rockford, IL, USA). Polyvinylidene difluoride
membranes were supplied from Gelman Laboratory (Ann Arbor, MI,
USA). The ECL chemiluminescent detection kit was purchased from
Amersham Pharmacia Biotech (Buckinghamshire, UK). The rat-specific
c-Jun siRNA and Stealth™ RNAi negative control duplexes were
provided by Invitrogen (Carlsbad, CA, USA). Dichlorofluorescein
diacetate (DCF-DA) was obtained from Invitrogen (Carlsbad, CA,
USA). N-Acetyl-L-cysteine (NAC) and carboxymethylcellulose (CMC)
sodium salt were obtained from Sigma-Aldrich (St Louis, MO, USA). All
other chemicals used were of analytical or the highest purity grade
available. Curcumin was dissolved in dimethyl sulfoxide (DMSO) and
was diluted further in culture medium.
2.2. Cell culture
The rat gastric mucosal RGM1 cells were kindly given by Prof. Ki
Baik Hahm (CHA University Bundang Medical Center, Seongnam,
Korea) and were maintained at 37°C in a humidified atmosphere
containing 5% CO2 and cultured in DMEM containing 10% (v/v) fetal
bovine serum and 100 U/ml penicillin. The cells were treated with
vehicle (DMSO) or curcumin.
2.3. Antibodies
Antibodies to the following proteins were used: β-actin, ERK
(Extracellular signal- regulated kinase)-1/2 (sc-135,900), phospho-
ERK (sc-101,760) and lamin B (SC-374015) from Santa Cruz
Biotechnology (Santa Cruz, CA, USA); phospho-c-Jun (#2361), c-Jun
(#9165), c-Fos (#2250), p38 Mitogen-activated protein kinase
(MAPK) (#9212), phospho-p38 MAPK (#9215), SAPK/JNK (c-Jun N-
terminal kinase) (#9252), phospho-SAPK/JNK (#4668) from Cell
Signaling (Denver, MA, USA); 15-PGDH (160615) from Cayman (Ann
Arbor, MI, USA).
2.4. Western blot analysis
RGM-1 cells (1.5×105 cells/ml) were plated in a 60 mm dish and
treated with curcumin when the cells were grown to approximately
60–70% confluence. After rinse with phosphate-buffered saline (PBS),
the cells were exposed to the lysis buffer [50 mM Tris–HCl (pH 7.4),
150 mM NaCl, 5 mM EDTA, 1% NP-40, and protease inhibitors] in the
ice for 30 min. After centrifugation at 13,000×g for 15 min, the
supernatant was collected and stored at−70°C until use. The protein
concentrationwas determined by using the bicinchoninic acid protein
assay kit (Pierce Biotechnology, Rockford, IL, USA). Protein samples
were electrophoresed on 10% sodium dodecyl sulfate-polyacrylamide
gel and transferred to polyvinylidene difluoride membrane at 300mA
for 3 h. The membrane was blocked in 5% non-fat dry milk
reconstituted in 0.1% Tween 20 in PBS (PBST) for 1 h, followed by
incubation with the indicated antibodies in PBST with 3% non-fat dry
milk. The membrane was then rinsed three times with PBST buffer for
10 min each. The washed membrane was incubated with 1:3000
dilution of the horseradish peroxidase-conjugated secondary anti-
body in PBSTwith3%non-fat drymilk for 1 h at room temperature. The
membrane was washed again three times in PBST buffer, and
transferred proteins were detected with an enhanced Peroxidase
Detection Western blot Detection Kit (ELPIS-BIOTECH, Daejeon,
Korea) or ECL Plus Western Blotting Reagent Pack (GE Healthcare,
Piscataway, NJ, USA) according to themanufacturer's instructions and
visualized with an X-ray film or the Imagequant™ LAS 4000 (Fujifilm
Life Science).
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Total RNA was isolated from RGM-1 cells using Trizol® (Invitro-
gen; Carlsbad, CA, USA). One microgram of total RNAwas used for the
complementary DNA synthesis using random primers. PCR was
performed following standard procedures. PCR conditions for 15-
PGDH and the house keeping gene GAPDH were as follows: 15-PGDH,
26 cycles of 94°C for 1 min; 60°C for 1 min and 72°C for 1 min. The
primer pairs and the size of the expected products were as follows
(forward and reverse, respectively): 15-PGDH, 5′-CAGGCAGA-
GAATGCTGAGTTC-3′ and 5′-GATGTTGAGCAG-GAACGCAGT-3′, 555
bp and GAPDH, 5′-TGAAGGTCGGTGT-CAACGGATTTGGC-3′ and 5′-
CATGTAGGCCATGAGGTCCACCAC-3′, 983 bp. Amplification products
were resolved by 1.0% agarose gel electrophoresis, stained with
ethidium bromide and photographed under ultraviolet light. Primers
were purchased from Bionics (Seoul, South Korea).
2.6. 15-PGDH promoter activity assay
The cultured cells were seeded at 60–70% confluence in 12-well
plates for 24 h before transfection. The cells were transiently co-
transfected with the 15-PGDH promoter construct ligated to the
luciferase gene (15-PGDH-2368/luc) or its deletion constructs (15-
PGDH-1024/luc, 15-PGDH-388/luc, and 15-PGDH-203/luc), and 0.5
μg of the pCMV-β galactosidase control vector using lipofectamine
RNAiMAX reagents (Thermo Fisher Scientific; Waltham, MA, USA)
according to the instructions supplied by the manufacturer. After
24 h of transfection, the cells were treated with curcumin for
additional 6 h and lysed in reporter lysis buffer (Promega;Madison,
WI, USA). The activity of firefly luciferase in the cell lysates was
measured using the luciferase reporter assay system according to
the manufacturer's instructions. The β-galactosidase assay was
conducted according to the supplier's instructions (Promega β-
galactosidase Enzyme Assay System) for normalizing the luciferase
assay.
2.7. Transient transfection
RGM-1 cells were seeded at a density of 1.5×105 cells in 60 mm
dish and grown to 50% confluence. c-Jun siRNA (20 nM) or negative
control siRNA (20 nM) was transfected into RGM-1 cells with
lipofectamine RNAiMAX reagents according to the manufacturer's
instructions. After 24 h transfection, cells were treated with curcumin
for additional 6 h and the cell lysiswas carried outwith the lysis buffer.
The target sequence for c-Jun siRNA was 5′-GGCATAATCGGATTCA-
CACG-3′ (forward) and 5′-CGAGGCCGTGATCTTCATAA-3′ (reverse)
(Genolution Pharmaceuticals, Seoul, South Korea).
2.8. Chromatin immunoprecipitation (ChIP) assay
RGM-1 cells were treated with curcumin for 6 h, followed by
fixation in 1% formaldehyde at 37°C for 10min to cross link histones
to DNA. After rinse with PBS, the cells were incubated in SDS lysis
buffer [50mMTris–HCl (pH 8.1), 1% SDS, 10mMEDTA and protease
inhibitors] for 10 min on ice, sonicated to generate DNA fragments
of 200–500 bp in length, and centrifuged at 13,000×g for 10 min.
ChIP dilution buffer [16.7 mM Tris–HCl (pH 8.1), 167 mM NaCl, 1.2
mM EDTA, 0.01% SDS, 1.1% Triton X-100 and protease inhibitors]
was added to each tube containing 100 μl of cross-linked fractions.
Samples were pre-immunoprecipitated with Protein G agarose
beads to preclear the chromatin for 1 h at 4°C. After centrifugation
at 7000×g for 1 min, supernatant was transferred into new tubes.
Each sample was immunoprecipitated with 5 μg of c-Jun antibody
or normal mouse IgG overnight at 4°C. Immune complexes were
precipitated with Protein Agarose G beads for 4 h at 4°C withrotation. Precipitates were washed once with low salt immune
complex wash buffer [20 mM Tris–HCl (pH 8.1), 150 mM NaCl, 2
mM EDTA, 0.1% SDS and 1% Triton X-100], once with high salt
immune complex wash buffer [20 mM Tris–HCl (pH 8.1), 500 mM
NaCl, 2 mM EDTA, 0.1% SDS and 1% Triton X-100], once with LiCl
immune complex wash buffer [10 mM Tris–HCl (pH 8.1), 1 mM
EDTA, 0.1% SDS, 1% Triton X-100, 0.5% NP-40, 1% IGEPAL-CA630, 1%
deoxycholic acid and 0.25 M LiCl] and twice with TE buffer [10 mM
Tris–HCl (pH 8.1) and 1 mM EDTA]. After extraction of antigen/
antibody complexes with elution buffer [0.1 M NaHCO3 and 1%
SDS], cross-linking was reversed by incubating at 65°C overnight.
DNAwas extracted using the AccuPrep Genomic DNA extraction kit
(Bioneer; Daejeon, South Korea) according to the manufacturer's
protocol. Washes and eluted DNA were used for PCR analysis using
specific primers for the AP-1 binding sites at the 15-PGDH
promoter region. The primers employed are as follows (forward
and reverse, respectively): c-Jun; 5’-CCAGACAATCGTCTCGCCCA-3′
and 5′-GGCTAGGTAACAGTTTAGCGAGGA-3′. Amplification prod-
ucts were resolved by 3.0% agarose gel electrophoresis, stained
with ethidium bromide and photographed under ultraviolet light.
2.9. Preparation of nuclear extracts
After treatment with curcumin, cells were washed with ice-cold
PBS, scraped in 1ml PBS and centrifuged at 13,000×g for 15min at 4°C.
Pellets were suspended in 100 μl of hypotonic buffer A [10 mMHEPES
(pH 7.8), 1.5 mM MgCl2, 10 mM KCl, 0.5 mM DTT, and 0.2 mM PMSF]
for 15min on ice, and 1 μl of 10%Nonidet P-40 solutionwas added for 5
min. The mixture was centrifuged at 12,000×g for 7 min at 4°C. The
pellets were washed with hypotonic buffer and resuspended in
hypertonic buffer C [20 mM HEPES (pH 7.8), 20% glycerol, 420 mM
NaCl, 1.5 mMMgCl2, 0.2 mM EDTA, 0.5 mMDTT, 0.2 mM PMSF] for 30
min on ice and centrifuged at 12,000×g for 7 min at 4°C. The
supernatant containing nuclear proteins was collected and stored at
−80°C. The protein concentration of the nuclear extract was
determined by the Bradford method using the Bio-Rad protein assay
kit (Bio-Rad Laboratories; Hercules, CA, USA).
2.10. Immunocytochemistry
RGM-1 cells were seeded at 3×104 cells/well in an 8 chamber slide.
RGM-1 cellswere pretreatedwithMAPK inhibitors for 2 h, followedby
treatment with curcumin 10 μM for additional 6 h. After fixation with
10% neutral-buffered formalin solution for 30 min at room temper-
ature, RGM-1 cells were incubated with blocking agents [0.1% Tween-
20 in PBS containing 5% bovine serum albumin], washedwith PBS and
then incubated with a diluted (1:100) p-c-Jun antibody for overnight
at 4°C. After washing with PBS (twice for 5 min each), samples were
incubatedwith a diluted (1:1000) FITC-goat anti-rabbit IgG secondary
antibody for 1 h. This was followed by washing cells with PBS (twice
for 5min each), and incubationwith propidium iodide (for 1min). The
signals were detected using a confocal microscope (Leica, Model: TCS
SP, Germany).
2.11. Bacteria strain and infection condition
Helicobacter pylori (H. pylori, ATCC 43504) with the typical shape,
gram-negative rods, possessing the CagA and VacA, was provided in a
frozen state by ATCC. The bacteriawere grownon tryptic soy agarwith
5% sheep blood agar (BDDiagnostics) andDent antibiotics supplement
(Oxoid) at 37°C under microaerophilic conditions (Campy-Pak
System; BBL). RGM-1 cells were incubated overnight in fresh serum-
and antibiotic-free DMEM and incubated with H. pylori at multiplic-
ities of infection (MOI) of 100:1 for 24 h.
Fig. 1. Effects of curcumin on 15-PGDH expression. (A) RGM-1 cells were treated with curcumin (10 μM) for indicated periods of time. The expression of 15-PGDH mRNA was
determined by RT-PCR.GAPDHwas used as an internal control. (B) The cell lysateswere subjected toWestern blot analysis. Actinwas used as an equal loading control for normalization.
(C) RGM-1 cellswere treatedwith concentration (5, 10, or 25 μM)of curcumin for 6 h. The cell lysateswere subjected toWestern blot analysis. Actinwas used as an equal loading control
.001).
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accumulation
The fluorescent probe DCF-DA was used to monitor the net
intracellular accumulation of ROS. The RGM-1 cells were treated with
curcumin for 6 h prior to H. pylori infection. The cells were rinsedwith
PBS and loaded with 10 mMDCF-DA for 30 min at 37°C to assess ROS-
mediated oxidation of DCF-DA to thefluorescentDCF. The intracellular
ROS accumulation was determined by fluorescent microscopy set at
488 nm for excitation and 530 nm for emission.
for normalization. Significantly different between the groups compared (**P<.01; ***P<Fig. 2.AP-1 plays an important role in induction of 15-PGDHby curcumin (A) A schematic rep
PGDHpromoter deletion constructs (−2368,−1024,−388 and−203) ligated to the luciferase g
h, and the cells were lysed for the measurement of luciferase activity. The luciferase activity w
curcumin for indicated time periods. The nuclear fraction andwhole lysateswere subjected toW
transfected with scrambled or c-Jun siRNA for 48 h and then treatedwith 10 μMof curcumin for
different between the groups compared (P<.001). (D) RGM-1 cells were treated with curcumin
c-Jun. ChIP-enriched DNA was amplified by PCR with specific primers for determining the AP-2.13. Animals study
Female C57BL/6 mice (5 weeks of age) were purchased from the
Central Lab. Animal (Seoul, South Korea) and were housed in a
climate-controlled quarters (24±1°C at 50% humidity) with a 12-h
light/12-h dark cycle and with free access to food and water. Animals
were handled in an accredited animal facility in accordance with the
Association for Assessment and Accreditation of Laboratory Animal
Care International policies (SNU-110511-4). After 1 week of adapta-
tion, 6-week old mice weighing 18–22 g were randomly assigned toresentation of the 15-PGDHpromoter. RGM-1 cells were co-transfectedwith 1 μg of 15-
ene and the pCMV-ß-galactosidase vector for 24 h. After incubationwith curcumin for 6
as normalized to ß-galactosidase activity. (B) RGM-1 cells were treated with 10 μM of
estern blot analysis. Lamin Bwas used as a nuclear proteinmarker. (C) RGM-1 cellswere
6 h. The expression of 15-PGDHwasmeasured byWestern blot analysis. ***Significantly
(10 μM) for 6 h. Total lysates were subjected to the ChIP assay using an antibody against
1 binding site present in the 15-PGDH promoter.
Fig. 3.Role of ERK1/2 and JNK in curcumin-induced expression of 15-PGDH. (A) RGM-1 cells were treatedwith curcumin (10 μM) for indicated time periods, and then the cell lysates
were subjected to Western blot analysis using antibodies against ERK, pERK, JNK, p-JNK, p38MAPK, p-p38MAPK and actin. (B) RGM-1 cells were treated with the MEK1/2 inhibitor,
U0126 (0.1 or 0.5 μM)or the JNK inhibitor, SP600125 (0.1 or 0.5 μM) for 2 h, followed by treatmentwith curcumin (10 μM) for additional 6 h. Total cell lysateswere subjected toWestern
blot analysiswith 15-PGDH antibody. The same blot was reprobedwith anti-β-actin as an internal control. (C) RGM-1 cells were pretreatedwithU0126 or SP600125 for 2 h, followed by
treatmentwith curcumin (10 μM) for additional 6 h. The nuclear fractionwas subjected toWestern blot analysiswith c-Jun and p-c-Jun antibodies. Lamin Bwas used as a nuclear protein
marker. (D) Immunocytochemical analysis was conducted to detect the nuclear localization of p-c-Jun (serine 63). RGM-1 cells were pretreated with MAPK inhibitors for 2 h, followed
by treatment with curcumin 10 μM for additional 6 h. After fixation with 10% neutral-buffered formalin solution, the cells were immunoblotted with p-c-Jun antibody (serine 63) and
FITC-goat anti-rabbit IgG secondary antibody. The signals were detected using a confocal microscope after incubation with propidium iodide.
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0.05% CMC solution on each treatment day. Based on the previous in
vivo study with curcumin [32,33], the mice were treated with vehicle
(0.05% CMC) or curcumin (25mg/kg) daily by gavage using oral Zonde
needle and sacrificed 2 weeks later. Mice were weighed three times a
week. Following euthanasia, stomach was resected.
2.14. Immunohistochemical staining
The dissected stomach tissues were prepared for immunohisto-
chemical analysis of the expression patterns of 15-PGDH. The sections
of 10% formalin-fixed, paraffin-embedded tissueswere placed on glass
slides and deparaffinized three times with xylene and rehydrated
through graded alcohol bath. The deparaffinized sections were heated
usingmicrowave and boiled twice for 6min in 10mmol/l citrate buffer
(pH 6.0) for antigen retrieval. To diminish nonspecific staining, each
sectionwas treatedwith 3% hydrogen peroxide and 4% peptone casein
blocking solution for 15 min. For the detection of respective protein
expression, slides were incubated with 15-PGDH antibody at room
temperature for 40min in Tris-buffered saline containing0.05% Tween
20 and then developed using respective horseradish peroxidase(HRP)-conjugated secondary antibodies (rabbit). The peroxidase
binding sites were detected by staining with 3,3′-diaminobenzidine
tetrahydrochloride. Finally, counterstaining was performed using
Mayer's hematoxylin.
2.15. Statistical analysis
When necessary, data were expressed as means±S.D. of at least
three independent experiments. The data were analyzed by one-way
ANOVA, and the statistical significance between groups was deter-
mined by Duncan's multiple range test. Statistical significance was
accepted at P<.05 and statistical analysis for single comparison was
performed using the Student's t-test.
3. Results
3.1. Curcumin induces 15-PGDH expression in RGM-1 cells
We first examined the effects of curcumin on the expression of 15-
PGDH. When RGM-1 cells were treated with curcumin, 15-PGDH
expression was transiently induced at both transcriptional (Fig. 1A)
Fig. 4. Curcumin induced 15-PGDH expression in mouse stomach in vivo. (A) The schematic overview of experimental protocol. Mice in the control group were fed normal diet and
received 0.05% CMC, p.o., for 2weeks (Group 1).Mice in Group 2 received a daily dose of 25mg/kg curcumin by using oral zonde needle for 2weeks. (B) Each gastric tissuewas lysed and
prepared forWestern blot analysis to assess the 15-PGDH expression. (C) Immunohistochemical detection of 15-PGDH inmouse stomach.Magnifications: x200 and x400. (D) Effects of
curcumin on phosphorylation of ERK and JNK and activation of AP-1 in mouse stomach in vivo. Significantly different between the groups compared (**P<.01; ***P<.001).
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concentration-dependent (Fig. 1C).
3.2. Induction of 15-PGDH is mediated through AP-1 activation
There are several binding sites of transcription factors present in
the promoter region of 15-PGDH [4]. The putative transcription factors
speculated to bind to these sites include CREB, Ets and AP-1 (Fig. 2A).
To investigate which transcription factor is essential for the regulation
of 15-PGDH expression, RGM-1 cells were transfected with 15-PGDH
promoter deletion constructs taggedwith the luciferase reporter gene
(15-PGDH-Luc). The cells were then treatedwith curcumin for 6 h and
the luciferase activitywasmeasured. As illustrated in Fig. 2A, curcumin
significantly enhanced the 15-PGDH-Luc activity. Compared to other
constructs, the cells transfected with 15-PGDH-2368 and 15-PGDH-
1024 constructs, which contain the AP-1 binding site, showed the
most pronounced promoter activity induced by curcumin (Fig. 2A).
Thus, AP-1 appears to be the key transcription factor involved in
curcumin-induced expression of 15-PGDH in RGM-1 cells. We also
measured the nuclear localization of c-Jun and c-Fos, key functional
subunits of AP-1, in curcumin-treatedRGM-1 cells. As shown in Fig. 2B,
c-Junwas accumulated in nucleus of these cells treatedwith curcumin.
The expression of c-Fos that forms a heterodimer with c-Jun was also
elevated upon curcumin treatment. Curcumin also induced expression
of CREB. To determine whether 15-PGDH upregulation by curcumin is
mediated via c-Jun activation, RGM-1 cells were transiently trans-
fectedwith c-Jun siRNAor its non-specific siRNA, and the expressionof15-PGDHwas analyzed byWestern blot analysis. Knockdown of c-Jun
by siRNA abrogated the expression of 15-PGDH induced by curcumin
(Fig. 2C). In order to determine whether curcumin-induced 15-PGDH
expression is mediated by direct binding of c-Jun to the 15-PGDH
promoter, the ChIP assay was carried out. As illustrated in Fig. 2D,
curcumin stimulated interaction of c-Jun with the AP-1 binding site
present in the 15-PGDH promoter. This finding lends further support
to the notion that AP-1 is essential for curcumin-induced upregulation
of 15-PGDH expression in RGM-1 cells.
3.3. Curcumin-induced expression of 15-PGDH is regulated by ERK1/2
and JNK
To elucidate the upstream signaling events that lead to activation
of AP-1 and subsequent induction of 15-PGDH expression, we
examined the phosphorylation of representative signal transducing
MAPKs known to be involved in activation of AP-1 signaling.We found
that curcumin treatment induced phosphorylation of ERK1/2 and JNK,
but p38 MAPK was not affected (Fig. 3A). The curcumin-induced 15-
PGDH expression was effectively suppressed by U0126 (MEK1/2-
ERK1/2 inhibitor) and the JNK inhibitor, SP600125 (Fig. 3B).Moreover,
pharmacologic inhibition of ERK and JNK abrogated curcumin-
induced nuclear translocation of total and phosphorylated c-Jun at
serine 63 as determined by Western blot analysis (Fig. 3C) and
immunofluorescent staining (Fig. 3D). These findings suggest that
curcumin-induced upregulation of 15-PGDH expression is mediated
via activation of the ERK1/2 and JNK-AP-1 axis.
Fig. 5. Comparative effects of curcumin and tetrahydrocurcumin on expression of signaling molecules involved in 15-PGDH expression. (A) The chemical structures of curcumin
and tetrahydrocurcumin. (B) RGM-1 cells were treated with curcumin (10 μM) or tetrahydrocurcumin (10 μM) for 6 h, and the whole lysates were subjected to Western blot analysis
using 15-PGDH antibody. ***Significantly different between the groups compared (P<.001). (C) RGM-1 cellswere treatedwith curcumin (10 μM)or tetrahydrocurcumin (10 μM) for 1 h
and then the whole lysates were subjected to Western blot analysis using ERK, p-ERK, JNK, p-JNK antibodies. (D) RGM-1 cells were treated with 10 μM each of curcumin or
tetrahydrocurcumin for 6 h, and then the nuclear fraction was subjected to Western blot analysis with c-Jun and p-c-Jun antibodies. Lamin B was used as a nuclear protein marker.
Fig. 6. Effect of curcumin onH. pylori-induced expression of DNMT-1 and 15-PGDH in RGM-1 cells (A) The RGM-1 cells were treated with curcumin (10 μM) for 6 h prior toH. pylori
infection (24 h), and the whole lysates were subjected toWestern blot analysis with antibodies against 15-PGDH and DNMT1. (B) Effect of curcumin on generation of ROS in H. pylori-
infected RGM-1 cells. RGM-1 cells were treated with curcumin (10 μM) for 6 h prior to H. pylori infection (24 h), and the intracellular ROS level was measured by DCF-DA staining.
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Fig. 7. Proposed scheme for induction of 15-PGDH by curcumin. Curcumin activates the ERK and JNK, which induces phosphorylation of c-Jun. c-Jun binds to the AP-1 binding sites
located in the promoter region of 15-PGDH, leading to induction of 15-PGDH via activation of transcriptional activity of AP-1.
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in mouse stomach
To examine whether curcumin could induce 15-PGDH expression
in gastricmucosa in vivo, C57BL/6micewere treatedwith curcumin by
gavage for 2 weeks (Fig. 4A). Administration of 25mg/kg curcumin by
oral zonde needle resulted in a marked induction of 15-PGDH
expression (Fig. 4B). The expression of 15-PGDH was observed in
the mucosal layer as determined by immunohistochemical analysis
(Fig. 4C). In addition, curcumin administration resulted in significant
increases in the phosphorylation of ERK and JNK in the stomach of
mice (Fig. 4D). Under the same experimental conditions, there was a
significant increase in the expression of c-Jun and c-Fos in the stomach
of curcumin-treated mice (Fig. 4D). We also noted that phosphory-
lation of c-Jun was increased following treatment with curcumin (Fig.
4D).3.5. The α,β-unsaturated carbonyl moiety of curcumin is critical for its
induction of 15-PGDH expression
A compound bearing an α,β-unsaturated carbonyl moiety can act
as a Michael reaction acceptor capable of covalently modifying
proteins [34]. This can modulate biological function of the target
proteins [35]. Curcumin has such a moiety, which has been known to
contribute to its biological activities. To determine whether an
electrophilic carbon center in the α,β-unsaturated carbonyl moiety
of curcumin plays an important role in induction of 15-PGDH, we
utilized tetrahydrocurcuminwhich lacks suchmoiety (Fig. 5A). Unlike
curcumin, its non-electrophilic analogue, tetrahydrocurcumin failed
to induce 15-PGDH expression (Fig. 5B). Moreover, tetrahydrocurcu-
min also could not induce phosphorylation of JNK and ERK (Fig. 5C)
and subsequent nuclear translocation and phosphorylation of c-Jun in
the nucleus of RGM-1 cells (Fig. 5D).
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restored by curcumin treatment
H. pylori has been known to cause gastritis and gastric cancer [36].
The expression of 15-PGDHwas found to be suppressed in theH. pylori
infected gastric cancer specimens, which was associated with
hypermethylation of CpG island in the promoter region of 15-PGDH
[37].We observed thatH. pylori infection suppressed the expression of
15-PGDH in the RGM-1 cells, and this was restored by curcumin
pretreatment (Fig. 6A). H. pylori infection has been known to induce
expression of DNMT1 [38]. Curcumin suppressed the H. pylori-
induced expression of DNMT1 (Fig. 6A). H. pylori has been known to
generate ROS [39]. Curcumin attenuated the generation of ROS
induced by H. pylori infection (Fig. 6B). These finding suggest that
the antioxidant activity of curcumin may account for its induction of
15-PGDH through suppression of DNMT1 as well as generation of ROS
in RGM-1 cells infected by H. pylori.
4. Discussion
Anti-inflammatory and anti-carcinogenic activities of curcumin
have been associated with down-regulation of COX-2-catalyzed PGE2
synthesis by blocking the activation of the proinflammatory tran-
scription factor, NF-κB [28]. In this study, we found that curcumin
induced the 15-PGDH expression in rat gastric mucosal RGM-1 cells
and inmouse stomach in vivo. Curcumin induced activation of ERK1/2
and JNK, and consequent enhancement of the phosphorylation and
nuclear translocation of c-Jun, which led to its binding to the promoter
region of 15-PGDH (Fig. 7). We also observed that H. pylori-induced
down-regulation of 15-PGDH was mitigated by curcumin pretreat-
ment. These findings suggest that anti-inflammatory effects of
curcumin are hence likely to be attributable to not only suppression
of COX-2-catalyzed PGE2 synthesis but also stimulation of 15-PGDH-
mediated catabolism of PGE2.
We attempted to elucidate mechanisms responsible for upregula-
tion of 15-PGDH expression by curcumin. There are several binding
sites located in the 15-PGDH promoter such as AP-1, Ets and CRE [4].
The AP-1 family transcription factors consist of dimers of Jun, Fos or
activating transcription factor (ATF) [40]. Jun proteins form hetero-
dimers with Fos- and ATF-family members, but can also homodimer-
ize. The Jun-Fos heterodimer has higher the stability than the Jun
homodimer [41]. The Jun-Fos dimer preferentially binds to the AP-1
element, whereas the Jun-ATF heterodimers or ATF homodimers
prefers to bind to the cAMP-responsive element [42]. c-Jun is
phosphorylated at serine/threonine of its amino-terminal activation
domain by JNK, which suppresses its proteasomal degradation via
ubiquitination [43]. Moreover, phosphorylation of serines 63 and 73
residues of c-Jun by JNK enhanced the binding affinity for the
transcriptional coactivator CREB-binding protein (CBP), thereby
stimulating its transcriptional activity [44,45]. However, c-Fos is
degraded by the 26S proteasomes in a ubiquitin-dependent pathway,
which was accelerated by its association with c-Jun and the
coordinated actions of the protein kinases such as MAPKs [46]. We
found that curcumin-induced activation of ERK and JNK was involved
in phosphorylation at Ser63 of c-Jun, which may account for
enhancement of stability and transcriptional activity of c-Jun, leading
to upregulation of 15-PGDH.
Chemically, curcumin is a bis-α,β-unsaturated β-diketone composed
of two aromatic rings linked together by two carbonyl groups. Such
peculiar structural feature of curcumin is essential for its exerting a wide
array of pharmacological activities [47]. Tetrahydrocurcumin is formedby
reductive metabolism after intraperitoneal administration of curcumin
[48]. Notably, tetrahydrocurcumin which lacks the α,β-unsaturated
carbonyl group failed to induce expression of 15-PGDH as well as
activation of AP-1. Therefore, it might be recommended that curcuminshould be administered orally rather than intraperitoneally to retain its
biological activity [48]. The α,β-unsaturated carbonyl moiety seems to
play an important role in induction of 15-PGDH by curcumin. In linewith
this finding, the electrophilic cyclopentenone prostaglandin 15d-PGJ2
induced the expression of 15-PGDH,while 9,10-dihydro-prostaglandin J2,
which lacks the α,β,-unsaturated carbonyl moiety, was unable to induce
15-PGDH expression in breast cancer cells [21].
Curcumin has anti-inflammatory effects against gastric diseases.
Curcumin suppressed water immersion and restraint stress-induced
mucosal damage and gastric blood flow in rats [49]. Moreover,
curcumin inhibited secretion of the pentagastrin or histamine-
stimulated gastric acid in rats [49]. H. pylori infection is one of the
causes of gastritis and stomach cancer [36]. Although the results of
clinical intervention studies are controversial, curcumin administra-
tion ameliorated dyspeptic symptoms with significant reduction of
serologic signs of gastric inflammation in H. pylori-infected gastritis
patients [50,51]. Curcumin suppressed the expression and production
of IL-17 by Th17 cells through induction of indoleamine 2,3-
dioxygenase in the H. pylori-infected human gastric mucosa [52].
Induction of COX-2 and down-regulation of 15-PGDH were observed
in H. pylori-positive subjects and gastric cancer specimens [37,53]. In H.
pylori-infected subjects, the suppression of 15-PGDH expression was
reversed by H. pylori eradication therapy [37]. In H. pylori-positive
subjects and gastric cancer patients, the 15-PGDH promoter exhibited
increasedmethylation, and thiswas attenuatedbyademethylation agent,
5-aza-2′-deoxycytidine [6]. We observed that curcumin restored the
expression of 15-PGDHwhichwas down-regulated byH. pylori infection.
Curcumin has also been known to function as a potential DNMT inhibitor,
thereby inducing hypomethylation of various genes [54,55]. For instance,
curcumin significantly induced demethylation of proximal promoter of
p21 via suppression of DNMT1, 3A and 3B, resulting in enhancement of
p21 expression and inhibition of growth of lung cancer cells [54]. In our
study, curcumin suppressed the expression of DNMT1, and this was
attributable to reduction of hypermethylation of CpG island induced byH.
pylori infection, which may involve anti-inflammatory effects of curcu-
min. In addition, Fat-1 mice capable of constitutively producing ω-3
polyunsaturated fatty acidswere less susceptible to theH. pylori induced-
down-regulation of 15-PGDH and stomach cancer development [56].
Then the question is how upregulation or restoration of 15-PGDH
confers protective effects against H. pylori. 15-PGDH oxidizes the 15-
hydroxy group of PGE2 to generate 15-keto PGE2. In our previous study,
15-keto PGE2 induced hemeoxygenase-1 through Nrf2 activation and
whereby it exerted cytoprotective and anti-inflammatory effects [57]. 15-
Keto PGE2 suppress the growth of breast cancer cells and xenograft tumor
growth through blockage of STAT3 activation [58]. Therefore, upregula-
tion of 15-PGDH or restoration of 15-PGDH by curcumin may lead to
accumulation of its end product 15-keto PGE2, which may contribute to
the protective effects against H. pylori infection.
In conclusion, curcumin induces expression of 15-PGDH in
cultured RGM-1 cells and mouse stomach in vivo through activation
of the ERK-JNK-AP-1 axis, which may account for new molecular
mechanism underlying its chemopreventive effects against
inflammation-associated carcinogenesis.
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